Amgen and Asher Biotherapeutics Launch Phase 1b Study for Lung Cancer Treatment

Amgen announced a Phase 1b clinical study to evaluate the safety and efficacy of combining Tarlatamab and AB248 in treating extensive stage small cell lung cancer. The study aims to determine the optimal dosage for further trials and could have significant implications for Amgen's stock performance and investor sentiment. The study is currently not recruiting, and further details are available on the ClinicalTrials portal.